File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Evidence-based approach of the use of Botulinum toxin type A (BTX) in cerebral palsy

TitleEvidence-based approach of the use of Botulinum toxin type A (BTX) in cerebral palsy
Authors
KeywordsBotox (Allergan)
Botulinum toxin type A (BTX)
Cerebral palsy (CP)
Children
Drooling
Dysport (Ipsen)
Muscle spasticity
Randomized controlled trials (RCT)
Issue Date2003
PublisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/13638491.asp
Citation
Pediatric Rehabilitation, 2003, v. 6 n. 2, p. 85-96 How to Cite?
AbstractA systematic review with the Sachett model of evidence-based medicine of the use of Botulinum toxin type A (BTX) for intervention in children with Cerebral Palsy (CP) is highlighted. Currently, the evidence showed that BTX is useful for treating pes equinus due to spasticity of the gastrocnemiussoleus muscles. However, careful patient selection and goals of treatment have to be addressed. More multi-centre clinical trials with standardized protocols are needed before widespread recommendation of the use of BTX in treating spasticity in CP can be made.
Persistent Identifierhttp://hdl.handle.net/10722/143561
ISSN
References

 

DC FieldValueLanguage
dc.contributor.authorWong, Ven_HK
dc.date.accessioned2011-12-12T03:51:54Z-
dc.date.available2011-12-12T03:51:54Z-
dc.date.issued2003en_HK
dc.identifier.citationPediatric Rehabilitation, 2003, v. 6 n. 2, p. 85-96en_HK
dc.identifier.issn1363-8491en_HK
dc.identifier.urihttp://hdl.handle.net/10722/143561-
dc.description.abstractA systematic review with the Sachett model of evidence-based medicine of the use of Botulinum toxin type A (BTX) for intervention in children with Cerebral Palsy (CP) is highlighted. Currently, the evidence showed that BTX is useful for treating pes equinus due to spasticity of the gastrocnemiussoleus muscles. However, careful patient selection and goals of treatment have to be addressed. More multi-centre clinical trials with standardized protocols are needed before widespread recommendation of the use of BTX in treating spasticity in CP can be made.en_HK
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/13638491.aspen_HK
dc.relation.ispartofPediatric Rehabilitationen_HK
dc.subjectBotox (Allergan)en_HK
dc.subjectBotulinum toxin type A (BTX)en_HK
dc.subjectCerebral palsy (CP)en_HK
dc.subjectChildrenen_HK
dc.subjectDroolingen_HK
dc.subjectDysport (Ipsen)en_HK
dc.subjectMuscle spasticityen_HK
dc.subjectRandomized controlled trials (RCT)en_HK
dc.subject.meshBotulinum Toxin Type A/*therapeutic useen_US
dc.subject.meshCerebral Palsy/*drug therapyen_US
dc.subject.meshEvidence-Based Medicineen_US
dc.subject.meshHumansen_US
dc.subject.meshNeuromuscular Agents/*therapeutic useen_US
dc.titleEvidence-based approach of the use of Botulinum toxin type A (BTX) in cerebral palsyen_HK
dc.typeArticleen_HK
dc.identifier.emailWong, V:vcnwong@hku.hken_HK
dc.identifier.authorityWong, V=rp00334en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/1363849031000139306en_HK
dc.identifier.pmid14534045en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0142027955&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume6en_HK
dc.identifier.issue2en_HK
dc.identifier.spage85en_HK
dc.identifier.epage96en_HK
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridWong, V=7202525632en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats